Multicenter, Randomized, Open Label, Parallel Study to Evaluate the Efficacy & Safety of IVF-M HP Inj. vs. Menopur® Inj.

Inclusion Criteria: * Adult women from 20 through 39 years of age at the screening * Subjects with the mean menstrual cycle day (MCD) of 25 to 35 days * Subjects with the Follicle Stimulating Hormone (FSH) concentration at the screening not exceeding the upper limit of the normal range (ULN) * Those diagnosed with infertility due to at least one of the following causes of infertility * Fallopian tubal factor * Infertility due to unknown cause * Male infertility * Complex factor * Subjects with the normal ovarian and uterine function * Subjects with not more than 3 times of the prior experience of in vitro fertilization * Subjects who had neither administered clomiphene citrate within 30 days nor gonadotropin within 14 days of the IP administration day * Subjects who were informed on the objective, method and effect etc. of the clinical study and signed the informed consent form Exclusion Criteria: * Subjects contraindicated to pregnancy * Subjects with BMI \> 30 (BMI; kg/m2) * Subjects diagnosed with polycystic ovary syndrome (PCOS) * Subjects who had experienced previously at least Grade 4 ovarian hyperstimulation syndrome (OHSS) * Subjects with poor response to gonadotropin (According to the Bologna criteria\* below) \*At least two of the following three features must be present: ① Advanced maternal age (\>=40 years) or any other risk factor for Poor Ovarian Response (POR) ② A previous POR (\<=3 oocyte with a conventional stimulation protocol) ③ An abnormal ovarian reserve test (i.e. Antral follicle Count (AFC) \< 5 follicles or Anti-Mullerian hormone (AMH) \< 0.5 ng/ml) * Those with abnormal metrorrhagia due to unknown cause at the screening * Subjects with submucosal uterine leiomyoma * Subjects with at least borderline ovarian tumor * Subjects with a history or malignant tumor in breast * Subjects with hydrosalpinx not removed by operation * Subjects with the Thyroid Stimulating Hormone (TSH) level out of the normal range at the screening * Subjects with a history of malignant tumor within 5 years prior to the screening * Subjects with severe disease potentially affecting the study such as pituitary insufficiency upon the investigator's judgment (e.g., heart failure, renal failure, hepatic failure or adrenal insufficiency etc.) * Subject with HIV- or syphilis-positive result at the screening * Subjects with a psychiatric disorder at the screening or those who failed in understanding the objective and method of this clinical study * Subject diagnosed with alcohol or drug abuse within 3 months prior to the screening * Subjects with a history of hypersensitivity to the investigational products of this clinical study * Subjects with a current or history of thromboembolism in vein or artery * Subjects with a history of genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption etc. * Subjects who had participated in another clinical study related to a drug administration after the enrollment in this study or who had participated in another clinical study within 3 months prior to the enrollment in this study * Others including the subjects for whom it was considered difficult to conduct this clinical study upon the principal investigator's judgment